877624-38-9

Basic information

• Product Name: methyl 5-(bromomethyl)nicotinate
• Synonyms: methyl 5-(bromomethyl)nicotinate;5-broMoMethyl-nicotinic acid Methyl ester;Methyl 5-(bromomethyl)nicotinate hydrobromide;3-Pyridinecarboxylic acid, 5-(bromomethyl)-, methyl ester
• CAS NO: 877624-38-9
• Molecular Formula: C₈H₈BrNO₂
• Molecular Weight: 230
• Mol File: 877624-38-9.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: methyl 5-(bromomethyl)nicotinate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 5-(bromomethyl)nicotinate(877624-38-9)
• EPA Substance Registry System: methyl 5-(bromomethyl)nicotinate(877624-38-9)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 877624-38-9(Hazardous Substances Data)

Usage

General Description

Methyl 5-(bromomethyl)nicotinate is a chemical compound with the molecular formula C9H9BrNO2. It belongs to the class of organic compounds known as pyridines and derivatives. methyl 5-(bromomethyl)nicotinate is a derivative of nicotinic acid, also known as vitamin B3, and is commonly used in the pharmaceutical industry as a building block for the synthesis of various drugs. Methyl 5-(bromomethyl)nicotinate is primarily utilized in the production of antineoplastic agents, which are used to treat cancer. It is also used in the synthesis of other biologically active molecules and pharmaceutical intermediates. methyl 5-(bromomethyl)nicotinate is a white solid with a melting point of around 109-113°C and is moderately soluble in water. However, it is important to handle this compound with care, as it is considered hazardous and may cause irritation to the skin, eyes, and respiratory system.

Upstream product

• 29681-45-6 5-methylnicotinic acid methyl ester 

Downstream Products

• 1446322-14-0 methyl 5-((4-formyl-6-methoxyphen-3-yloxy)methyl)nicotinate 
• 912934-74-8 C₁₅H₁₅NO₃ 

Relevant articles and documents

Resin and Magnetic Nanoparticle-Based Free Radical Probes for Glycan Capture, Isolation, and Structural Characterization

By combining the merits of solid supports and free radical activated glycan sequencing (FRAGS) reagents, we develop a multifunctional solid-supported free radical probe (SS-FRAGS) that enables glycan enrichment and characterization. SS-FRAGS comprises a solid support, free radical precursor, disulfide bond, pyridyl, and hydrazine moieties. Thio-activated resin and magnetic nanoparticles (MNPs) are chosen as the solid support to selectively capture free glycans via the hydrazine moiety, allowing for their enrichment and isolation. The disulfide bond acts as a temporary covalent linkage between the solid support and the captured glycan, allowing the release of glycans via the cleavage of the disulfide bond by dithiothreitol. The basic pyridyl functional group provides a site for the formation of a fixed charge, enabling detection by mass spectrometry and avoiding glycan rearrangement during collisional activation. The free radical precursor generates a nascent free radical upon collisional activation and thus simultaneously induces systematic and predictable fragmentation for glycan structure elucidation. A radical-driven glycan deconstruction diagram (R-DECON) is developed to visually summarize the MS2 results and thus allow for the assembly of the glycan skeleton, making the differentiation of isobaric glycan isomers unambiguous. For application to a real-world sample, we demonstrate the efficacy of the SS-FRAGS by analyzing glycan structures enzymatically cleaved from RNase-B.

Biomimetic reagents for the selective free radical and acid-base chemistry of glycans: Application to glycan structure determination by mass spectrometry

Nature excels at breaking down glycans into their components, typically via enzymatic acid-base catalysis to achieve selective cleavage of the glycosidic bond. Noting the importance of proton transfer in the active site of many of these enzymes, we describe a sequestered proton reagent for acid-catalyzed glycan sequencing (PRAGS) that derivatizes the reducing terminus of glycans with a pyridine moiety possessing moderate proton affinity. Gas-phase collisional activation of PRAGS-derivatized glycans predominately generates C1-O glycosidic bond cleavages retaining the charge on the reducing terminus. The resulting systematic PRAGS-directed deconstruction of the glycan can be analyzed to extract glycan composition and sequence. Glycans are also highly susceptible to dissociation by free radicals, mainly reactive oxygen species, which inspired our development of a free radical activated glycan sequencing (FRAGS) reagent, which combines a free radical precursor with a pyridine moiety that can be coupled to the reducing terminus of target glycans. Collisional activation of FRAGS-derivatized glycans generates a free radical that reacts to yield abundant cross-ring cleavages, glycosidic bond cleavages, and combinations of these types of cleavages with retention of charge at the reducing terminus. Branched sites are identified with the FRAGS reagent by the specific fragmentation patterns that are observed only at these locations. Mechanisms of dissociation as well as application of the reagents for both linear and highly branched glycan structure analysis are investigated and discussed. The approach developed here for glycan structure analysis offers unique advantages compared to earlier studies employing mass spectrometry for this purpose.

2-SULFANYL-BENZOIMIDAZOL-1-YL-ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS

The invention relates to 2-sulfanyl-benzoimidazol-1-yl-acetic acid derivatives and their use as potent "chemoattractant receptor-homologous molecule expressed on Th2 cells" antagonists in the treatment of prostaglandin mediated diseases, to pharmaceutical compositions containing these derivatives and to processes for their preparation.